<DOC>
	<DOC>NCT01451619</DOC>
	<brief_summary>This study will assess the effect of MK-0524 relative to placebo, on signs and symptoms of rosacea and to determine the safety and tolerability profile of MK-0524 in participants with rosacea.</brief_summary>
	<brief_title>A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>Moderate to severe erythematotelangiectatic rosacea with moderate to severe erythema of facial lesion Generally healthy excluding rosacea Presence of telangiectasia Five or less facial inflammatory lesions Able to restrict diet in order to avoid foods/drinks (including alcohol) that are known to exacerbate the signs/symptoms of rosacea Females of childbearing potential must have negative serum pregnancy test and agree to use one form of contraception Diagnosis of skin disorders, including psoriasis, acne vulgaris, perioral dermatitis or atopic dermatitis that would interfere with the clinical evaluations of rosacea Using and unable to discontinue use of phosphodiesterase (PDE) 4 inhibitors, theophylline, niacin greater than 500 mg/day Known or suspected excessive alcohol intake Sensitivity to tetracyclines Ocular rosacea and/or blepharitis/meibomianitis Pregnant or breastfeeding Perimenopausal and has symptoms that cause flushing that may affect rosacea Initiated hormonal method of birth contraception within 4 months of baseline, discontinues use during the course of the study, or changes hormonal method within 4 months Active mycobacterial infection of any species within 3 years History of mycobacterium tuberculosis infection History of recurrent bacterial infection Congenital or acquired immunodeficiency common variable immunodeficiency (CVID), Hepatitis B surface antigen positive or Hepatitis B core antibody positive Human immunodeficiency virus (HIV) infection Positive for hepatitis C antibodies Malignancy or has had a history of malignancy greater than 3 years prior Will continue to use any of the following treatments during the study: Systemic retinoids, therapeutic vitamin A supplements of greater than 10,000 units/day, systemic steroids, systemic antibiotics known to have an impact on the severity of facial rosacea, systemic treatment for acne, topical steroids, topical retinoids, topical acne treatments including prescription and overthecounter (OTC) preparations, topical antiinflammatory agents, topical antibiotics, topical imidazole antimycotics, cryodestruction or chemodestruction, dermabrasion, photodynamic therapy, acne surgery, intralesional steroids, Xray therapy, pulsedye laser, intense pulse light, astringents, abrasives, benzoyl peroxide products, sulfur containing washes, eye washes, Beta blockers, vasodilators, vasoconstrictors and/or chronic use (&gt;14 days) of topical or systemic antiinflammatory agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>